Stem cell trial for rare bleeding disorder pulled before it began
NCT ID NCT06813157
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study planned to test whether infusions of mesenchymal stem cells could safely help people with refractory immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The trial was withdrawn before enrolling any participants, so no results are available. It would have given five stem cell infusions over several weeks and tracked platelet counts and bleeding for a year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- mesenchymal stem cells (MSCs)
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ITP - IMMUNE THROMBOCYTOPENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dongguan Taixin Hospital
Guangdong, Guangdong, 523125, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New combo therapy aims to boost platelets in ITP patients
- Gene-Edited immune cells take on autoimmune blood diseases
- New combo aims to free ITP patients from lifelong medication
- New drug OM336 aims to tame overactive immune system
- Promising ITP drug trial pulled before it even started
- New hope for teens with rare bleeding disorder: experimental drug enters final testing